The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival
Open accessAbstract
Significance: Improving survival of patients with glioblastoma (GBM) using antiangiogenic therapy remains a challenge. In this study we show that dual blockade of angiopoietin-2 and vascular endothelial growth factor delays tumor growth and enhances survival benefits through reprogramming of tumor-associated macrophages toward an antitumor phenotype as well as by pruning immature tumor vessels. The antitumor immunomodulatory potential of this dual blockade supports clinical testing of this approach for GBM with other immunotherapeutic approaches such as checkpoint blockers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Experimental data indicate that VEGF and ANG2 might cooperate to induce tumour immunosuppression and that this effect might be dependent on the relative levels of these cytokines in the TME35–37”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Second, ANG2 is co-expressed with VEGF in many human solid tumours, such as glioblastoma35, HCC81, and CRC82”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The overall number of T cells in the tumour mass, however, was unchanged16,35,36.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the therapeutic benefits of dual VEGF–ANG2 blockade seem to be conferred through the lymphoid (for example, in breast and colon tumour models16) and/or myeloid cell populations (in both central nervous system (CNS) and non-CNS tumour models16,35,36,90).”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“reprogramming of pro-tumour, M2-like TAMs towards an anticancer M1 phenotype has been shown to be a major contributor to the therapeutic efficacy of dual antiangiogenic therapy targeting VEGF and ANG2, independent of the tumour model used16,35,36.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [35]
Experimental — accuracy not yet measured
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
NCBI GEO: archive for functional genomics data sets—update
Barrett, T., Wilhite, S. E., Ledoux, P., Evangelista, C., Kim, I. F., Tomashevsky, M., Marshall, K. A., Phillippy, K. H., Sherman, P. M., Holko, M., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1193 · Cited by 10,418
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Macrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
Self-citationRapid Prototyping of Microfluidic Systems in Poly(dimethylsiloxane)
Duffy, D. C., McDonald, J. C., Schueller, O. J. A., & Whitesides, G. M. (1998) · Analytical Chemistry · doi:10.1021/ac980656z · Cited by 5,288
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
How to measure and predict the molar absorption coefficient of a protein
Pace, C. N., Vajdos, F., Fee, L., Grimsley, G., & Gray, T. (1995) · Protein Science · doi:10.1002/pro.5560041120 · Cited by 3,907
Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis
Maisonpierre, P. C., Suri, C., Jones, P. F., Bartunkova, S., Wiegand, S. J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T. H., Papadopoulos, N., et al. (1997) · Science · doi:10.1126/science.277.5322.55 · Cited by 3,570
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Chinot, O. L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., Carpentier, A. F., Hoang-Xuan, K., Kavan, P., Cernea, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308345 · Cited by 2,557
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,466
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Carmeliet, P., & Jain, R. K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3455 · Cited by 1,675
Self-citationAntiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
Self-citationKreisl, T. N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M., Butman, J. A., Camphausen, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3055 · Cited by 1,577
Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system
Augustin, H. G., Young Koh, G., Thurston, G., & Alitalo, K. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2639 · Cited by 1,465
De Palma, M., Venneri, M. A., Galli, R., Sergi, L. S., Politi, L. S., Sampaolesi, M., & Naldini, L. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.002 · Cited by 1,311
Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5028 · Cited by 1,241
Murat, A., Migliavacca, E., Gorlia, T., Lambiv, W. L., Shay, T., Hamou, M.-F., de Tribolet, N., Regli, L., Wick, W., Kouwenhoven, M. C. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7164 · Cited by 721
Dvorak, H. F., Nagy, J. A., Dvorák, J., & Dvořàk, A. M. (1988) · PubMed Central · Cited by 679
FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme
Cohen, M. H., Shen, Y. L., Keegan, P., & Pazdur, R. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0121 · Cited by 655
The interaction of anticancer therapies with tumor-associated macrophages
Mantovani, A., & Allavena, P. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20150295 · Cited by 616
Batchelor, T. T., Mulholland, P., Neyns, B., Nabors, L. B., Campone, M., Wick, A., Mason, W., Mikkelsen, T., Phuphanich, S., Ashby, L. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.2464 · Cited by 614
Self-citationVenneri, M. A., Palma, M. D., Ponzoni, M., Pucci, F., Scielzo, C., Zonari, E., Mazzieri, R., Doglioni, C., & Naldini, L. (2007) · Blood · doi:10.1182/blood-2006-10-053504 · Cited by 505
Fluid forces control endothelial sprouting
Song, J. W., & Munn, L. L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105316108 · Cited by 498
Self-citationSchaefer, W., Regula, J. T., Bähner, M., Schanzer, J., Croasdale, R., Dürr, H., Gassner, C., Georges, G., Kettenberger, H., Imhof-Jung, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019002108 · Cited by 482
Self-citationYuan, F., Salehi, H. A., Boucher, Y., Vasthare, U. S., Tuma, R. F., & Jain, R. K. (1994) · PubMed · Cited by 463
Self-citationWakimoto, H., Kesari, S., Farrell, C. J., Curry, W. T., Zaupa, C., Aghi, M., Kuroda, T., Stemmer-Rachamimov, A., Shah, K., Liu, T.-C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3886 · Cited by 361
Self-citationAnti-VEGF/VEGFR Therapy for Cancer: Reassessing the Target
Sitohy, B., Nagy, J. A., & Dvorak, H. F. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3406 · Cited by 360
Liang, W.-C., Wu, X., Peale, F. V., Lee, C. V., Meng, Y. G., Gutierrez, J., Fu, L., Malik, A. K., Gerber, H.-P., Ferrara, N., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508199200 · Cited by 346
Coffelt, S. B., Tal, A. O., Scholz, A., De Palma, M., Patel, S., Urbich, C., Biswas, S. K., Murdoch, C., Plate, K. H., Reiss, Y., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0012 · Cited by 343
The molecular profile of microglia under the influence of glioma
Li, W., & Graeber, M. B. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos116 · Cited by 340
Pucci, F., Venneri, M. A., Biziato, D., Nonis, A., Moi, D., Sica, A., Di Serio, C., Naldini, L., & De Palma, M. (2009) · Blood · doi:10.1182/blood-2009-01-200931 · Cited by 328
Peterson, T. E., Kirkpatrick, N. D., Huang, Y., Farrar, C. T., Marijt, K. A., Kloepper, J., Datta, M., Amoozgar, Z., Seano, G., Jung, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525349113 · Cited by 317
Self-citationGaussia luciferase reporter assay for monitoring biological processes in culture and in vivo
Tannous, B. A. (2009) · Nature Protocols · doi:10.1038/nprot.2009.28 · Cited by 303
A secreted luciferase for ex vivo monitoring of in vivo processes
Wurdinger, T., Badr, C., Pike, L., de Kleine, R., Weissleder, R., Breakefield, X. O., & Tannous, B. A. (2008) · Nature Methods · doi:10.1038/nmeth.1177 · Cited by 284
Tolaney, S. M., Boucher, Y., Duda, D. G., Martin, J. D., Seano, G., Ancukiewicz, M., Barry, W. T., Goel, S., Lahdenrata, J., Isakoff, S. J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518808112 · Cited by 258
Self-citationComplementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and Growth
Hashizume, H., Falcón, B. L., Kuroda, T., Baluk, P., Coxon, A., Yu, D., Bready, J. V., Oliner, J. D., & McDonald, D. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1977 · Cited by 251
Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade
Rigamonti, N., Kadioglu, E., Keklikoglou, I., Wyser Rmili, C., Leow, C. C., & De Palma, M. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.06.059 · Cited by 247
Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy
Emblem, K. E., Mouridsen, K., Bjornerud, A., Farrar, C. T., Jennings, D., Borra, R. J. H., Wen, P. Y., Ivy, P., Batchelor, T. T., Rosen, B. R., et al. (2013) · Nature Medicine · doi:10.1038/nm.3289 · Cited by 246
Self-citationOtt, P. A., Hodi, F. S., & Buchbinder, E. I. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00202 · Cited by 242
Daly, C., Eichten, A., Castanaro, C., Pasnikowski, E., Adler, A., Lalani, A. S., Papadopoulos, N., Kyle, A. H., Minchinton, A. I., Yancopoulos, G. D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2064 · Cited by 230
Lu-Emerson, C., Snuderl, M., Kirkpatrick, N. D., Goveia, J., Davidson, C., Huang, Y., Riedemann, L., Taylor, J., Ivy, P., Duda, D. G., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not082 · Cited by 226
Self-citationCoffelt, S. B., Chen, Y.-Y., Muthana, M., Welford, A. F., Tal, A. O., Scholz, A., Plate, K. H., Reiss, Y., Murdoch, C., De Palma, M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002802 · Cited by 220
Microglia/macrophages promote glioma progression
Zhai, H., Heppner, F. L., & Tsirka, S. E. (2011) · Glia · doi:10.1002/glia.21117 · Cited by 209
Kienast, Y., Klein, C., Scheuer, W., Raemsch, R., Lorenzon, E., Bernicke, D., Herting, F., Yu, S., The, H. H., Martarello, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0081 · Cited by 201
Self-citationLu-Emerson, C., Duda, D. G., Emblem, K. E., Taylor, J. W., Gerstner, E. R., Loeffler, J. S., Batchelor, T. T., & Jain, R. K. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.9575 · Cited by 179
Self-citationTargeting Vascular Pericytes in Hypoxic Tumors Increases Lung Metastasis via Angiopoietin-2
Keskin, D., Kim, J., Cooke, V. G., Wu, C.-C., Sugimoto, H., Gu, C., De Palma, M., Kalluri, R., & LeBleu, V. S. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.01.035 · Cited by 165
Brown, J. L., Cao, Z. A., Pinzon-Ortiz, M. C., Kendrew, J., Reimer, C., Wen, S., Zhou, J. Q., Tabrizi, M. A., Emery, S. C., McDermott, B., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0554 · Cited by 154
Kodack, D. P., Chung, E., Yamashita, H., Incio, J., Duyverman, A. M. M. J., Song, Y., Farrar, C. T., Huang, Y., Ager, E., Kamoun, W., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216078109 · Cited by 153
Self-citationAstrocytic Regulation of Human Monocytic/Microglial Activation
Kostianovsky, A. M., Maier, L. M., Anderson, R. C. E., Bruce, J. N., & Anderson, D. E. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5425 · Cited by 149
Microglial/macrophage expression of interleukin 10 in human glioblastomas
Wagner, S., Czub, S., Greif, M., Vince, G. H., S�ss, N., Kerkau, S., Rieckmann, P., Roggendorf, W., Roosen, K., & Tonn, J. C. (1999) · International Journal of Cancer · Cited by 149
Chae, S.-S., Kamoun, W. S., Farrar, C. T., Kirkpatrick, N. D., Niemeyer, E., de Graaf, A. M. A., Sorensen, A. G., Munn, L. L., Jain, R. K., & Fukumura, D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3073 · Cited by 135
Self-citationLambiv, W. L., Vassallo, I., Delorenzi, M., Shay, T., Diserens, A., Misra, A., Feuerstein, B. G., Murat, A., Migliavacca, E., Hamou, M., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor036 · Cited by 134
Tumor Stroma, Tumor Blood Vessels, and Antiangiogenesis Therapy
Dvorak, H. F. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000124 · Cited by 127
Anastomosis of endothelial sprouts forms new vessels in a tissue analogue of angiogenesis
Song, J. W., Bazou, D., & Munn, L. L. (2012) · Integrative Biology · doi:10.1039/c2ib20061a · Cited by 105
Self-citationMeisen, W. H., Wohleb, E. S., Jaime‐Ramirez, A. C., Bolyard, C. M., Yoo, J. Y., Russell, L., Hardcastle, J. J., Dubin, S. N., Muili, K. A., Yu, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3118 · Cited by 103
Wu, J., & Waxman, D. J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1005521 · Cited by 102
Gabrusiewicz, K. R., Liu, D., Cortes‐Santiago, N., Hossain, M. B., Conrad, C. A., Aldape, K., Fuller, G. N., Marini, F. C., Alonso, M. M., Idoate, M. A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1893 · Cited by 88
Wick, W., Brandes, A., Gorlia, T., Bendszus, M., Sahm, F., Taal, W., TAPHOORN, M. J. B., Dômont, J., Idbaïh, A., Campone, M., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov306 · Cited by 80
Thomas, M., Kienast, Y., Scheuer, W., Bähner, M., Kaluza, K., Gassner, C., Herting, F., Brinkmann, U., Seeber, S., Kavlie, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054923 · Cited by 73
Vessel calibre—a potential MRI biomarker of tumour response in clinical trials
Emblem, K. E., Farrar, C. T., Gerstner, E. R., Batchelor, T. T., Borra, R., Rosen, B. R., Sorensen, A. G., & Jain, R. K. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.126 · Cited by 61
Self-citationVegetables and fruit and human cancer: Update of an Italian study
Vecchia, C. L., Chatenoud, L., Franceschi, S., Soler, M., Parazzini, F., & Negri, E. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990702)82:1<6::aid-ijc2>3.0.co;2-3 · Cited by 59
Grenga, I., Kwilas, A. R., Donahue, R. N., Farsaci, B., & Hodge, J. W. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0096-7 · Cited by 26
Hidalgo, M. M., Tourneau, C. L., Massard, C., Boni, V., Calvo, E., Albanell, J., Taus, Á., Sablin, M., Varga, A., Bahleda, R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.2525 · Cited by 14
Self-citationIncreased number of microglia in the brain of severe combined immunodeficient (SCID) mice
Lorke, D. E., Ip, C. W., & Schumacher, U. (2008) · Histochemistry and Cell Biology · doi:10.1007/s00418-008-0463-2 · Cited by 13
Affronti, M. L., Desjardins, A., Friedman, H. S., Peters, K. B., Herndon, J. E., McSherry, F., Lipp, E., Brickhouse, A., Massey, W. C., Miller, E. P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.2074 · Cited by 6
Research works printed but not linked: 1
- 10.1002/(SICI)1097-0215(19990702)82:1<12::AID-IJC3>3.0.CO;2-O · doi:10.1002/(sici)1097-0215(19990702)82:1<12::aid-ijc3>3.0.co;2-o
Cited by
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Self-citationTumor angiogenesis: causes, consequences, challenges and opportunities
Lugano, R., Ramachandran, M., & Dimberg, A. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03351-7 · Cited by 1,986
Microenvironmental regulation of tumour angiogenesis
De Palma, M., Biziato, D., & Petrova, T. V. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.51 · Cited by 1,847
Metadata
- Authors
- Kloepper, J., Riedemann, L., Amoozgar, Z., Seano, G., Susek, K., Yu, V., Dalvie, N., Amelung, R. L., Datta, M., Song, J. W., Askoxylakis, V., Taylor, J. W., Lu-Emerson, C., Batista, A., Kirkpatrick, N. D., Jung, K., Snuderl, M., Muzikansky, A., Stubenrauch, K. G., Krieter, O., Wakimoto, H., Xu, L., Munn, L. L., Duda, D. G., Fukumura, D., Batchelor, T. T., & Jain, R. K.
- Affiliations
- Harvard University (US)
- Tufts University (US)
- Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114;
- Roche Pharma AG (Germany) (DE)
- ORCID
- Kloepper, Jonas
- Riedemann, Lars
- Amoozgar, Zohreh
- Seano, Giorgio
- Susek, Katharina
- Yu, Veronica
- Dalvie, Nisha
- Datta, Meenal
- Song, Jonathan W.
- Askoxylakis, Vasileios
- Taylor, Jennie W.
- Batista, Ana
- Jung, Keehoon
- Snuderl, Matija
- Muzikansky, Alona
- Stubenrauch, Kay G.
- Krieter, Oliver
- Wakimoto, Hiroaki
- Xu, Lei
- Munn, Lance L.
- Duda, Dan G.
- Fukumura, Dai
- Batchelor, Tracy T.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2016-04-04
- Volume
- 113
- Issue
- 16
- Pages
- 4476-4481
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC4843473
- OpenAlex
- W2326749252
- Cited by
- 357
- References
- 69
- Citations by year
- 2026: 8 · 2025: 31 · 2024: 29 · 2023: 38 · 2022: 36 · 2021: 50 · 2020: 39 · 2019: 35 · 2018: 40 · 2017: 35 · 2016: 15
- FWCI
- 21.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- HHS | National Institutes of Health (P50CA165962, P01CA080124, KCA125440, R01CA126642, R35CA197743, R01CA159258, R01CA096915, R01HL106584, S10-RR027070, T32-CA073479, K12CA090354)
- U.S. Department of Defense (W81XWH-10-1-0016)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- glioblastoma, angiopoietin-2, vascular endothelial growth factor, bispecific antibodies, anti-VEGF therapy resistance, tumor-associated macrophages, microglia, tumor immune microenvironment, tumor vasculature, tumor growth inhibition, survival
- MeSH terms
- Animals, Antibodies, Neoplasm, Antineoplastic Agents, Glioblastoma, Humans, Macrophages, Neoplasm Proteins, Neoplasms, Experimental, Ribonuclease, Pancreatic, Antibodies, Bispecific, Xenograft Model Antitumor Assays, Vesicular Transport Proteins, Vascular Endothelial Growth Factor A, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.